These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 34688262)

  • 21. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
    Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
    Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
    Yu W; Tao Q; Zhang Y; Yi F; Feng L
    J Oncol; 2021; 2021():9959946. PubMed ID: 34603452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
    Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer.
    Cui Z; Wang Q; Deng M; Meng E; Liu S; Niu B; Han Q
    Immunotherapy; 2023 Feb; 15(3):127-133. PubMed ID: 36722149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient.
    Zhang EL; Zhang ZY; Li J; Huang ZY
    Onco Targets Ther; 2020; 13():12477-12487. PubMed ID: 33311988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report.
    Lin S; Chen W; Chen Z; Liang J; Zhong L; Jiang M
    Ann Transl Med; 2022 Mar; 10(6):380. PubMed ID: 35433988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report.
    Du Y; Zhang X; Zhang Y; Li W; Hu W; Zong L; Zhao J
    Hum Vaccin Immunother; 2022 Nov; 18(6):2121122. PubMed ID: 36162043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
    Front Oncol; 2022; 12():917353. PubMed ID: 36226061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report.
    Baik H; Lee HJ; Park J; Park HY; Park J; Lee S; Bae KB
    Mol Clin Oncol; 2021 Nov; 15(5):243. PubMed ID: 34650810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
    Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
    BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
    Kim RD; Kovari BP; Martinez M; Xie H; Sahin IH; Mehta R; Strosberg J; Imanirad I; Ghayouri M; Kim YC; Kim DW
    Eur J Cancer; 2022 Jul; 169():93-102. PubMed ID: 35526308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
    Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
    Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
    J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
    BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.